Impaired gp100-Specific CD8+ T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model

Journal of Investigative Dermatology

Volumn 135, Issue 11, 2015, Pages 2785-2793

  Mairhofer, David G ^a   Ortner, Daniela ^a   Tripp, Christoph H ^a,b   Schaffenrath, Sandra ^a,b   Fleming, Viktor ^a,c   Heger, Lukas ^a,c   Komenda, Kerstin ^a   Reider, Daniela ^a,b   Dudziak, Diana ^c   Chen, Suzie ^d   Becker, Jürgen C ^e   Flacher, Vincent ^a,f   Stoitzner, Patrizia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD45 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INDUCIBLE NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; MELANOCYTE PROTEIN PMEL 17; SUPPRESSOR FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; MOUSE MODEL; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN CARCINOGENESIS; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; RANDOMIZATION; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ANALYSIS OF VARIANCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GP100 MELANOMA ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RANDOM ALLOCATION; SUPPRESSOR FACTORS, IMMUNOLOGIC; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 84947026838     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.241     Document Type: Article

References (39)

1. Ahmadzadeh M, Johnson LA, Heemskerk B et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44
2. Akbar AN, Henson SM (2011) Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 11: 289-95
3. Bakker AB, Schreurs MW, de Boer AJ et al. (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-9
4. Becker JC, Houben R, Schrama D et al. (2010) Mouse models for melanoma: a personal perspective. Exp Dermatol 19:157-64
5. Boon T, Coulie PG, Van den Eynde BJ et al. (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208
6. Burnet M (1957) Cancer; a biological approach. I. The processes of control. Br Med J 1:779-86
7. Chen S, Zhu H, Wetzel WJ et al. (1996) Spontaneous melanocytosis in transgenic mice. J Investig Dermatol Symp Proc 106:1145-51
8. Cohen-Solal KA, Reuhl KR, Ryan KB et al. (2001) Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase. Pigment Cell Res 14:466-74
9. Dunn GP, Bruce AT, Ikeda H et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 3:991-8
10. Fourcade J, Sun Z, Benallaoua M et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175-86
11. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-74
12. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nature Rev Immunol 12:253-68
13. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014-22
14. Haanen JB, Baars A, Gomez R et al. (2006) Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55:451-8
15. Kawakami Y, Dang N, Wang X et al. (2000) Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 23:17-27
16. Kimpfler S, Sevko A, Ring S et al. (2009) Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 183:6330-7
17. Klages K, Mayer CT, Lahl K et al. (2010) Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 70:7788-99
18. Ladanyi A, Somlai B, Gilde K et al. (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10:521-30
19. Landsberg J, Gaffal E, Cron M et al. (2010) Autochthonous primary and metastatic melanomas in Hgf-Cdk4 R24C mice evade T-cell-mediated immune surveillance. Pigment Cell Melanoma Res 23:649-60
20. Marin YE, Namkoong J, Cohen-Solal K et al. (2006) Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 18:1279-86
21. Motz GT, Coukos G (2013) Deciphering and reversing tumor immune suppression. Immunity 39:61-73
22. Namkoong J, Shin SS, Lee HJ et al. (2007) Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67:2298-305
23. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-67
24. Overwijk WW, Theoret MR, Finkelstein SE et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569-80
25. Pollock PM, Cohen-Solal K, Sood R et al. (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34:108-12
26. Prickett TD, Samuels Y (2012) Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 18:4240-6
27. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D et al. (2009) Self-antigenspecific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206:849-66
28. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-15
29. Schiffner S, Chen S, Becker JC et al. (2012) Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp Dermatol 21:786-8
30. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565-70
31. Senovilla L, Vacchelli E, Galon J et al. (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1:1323-43
32. Umansky V, Abschuetz O, Osen W et al. (2008) Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 68:9451-8
33. van Houdt IS, Sluijter BJ, Moesbergen LM et al. (2008) Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123:609-15
34. Vesely MD, Kershaw MH, Schreiber RD et al. (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-71
35. Willimsky G, Blankenstein T (2007) The adaptive immune response to sporadic cancer. Immunol Rev 220:102-12
36. Xiao H, Peng Y, Hong Y et al. (2011) Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J Immunol 187:1788-96
37. Yang L, Pang Y, Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31:220-7
38. Youn JI, Nagaraj S, Collazo M et al. (2008) Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-802
39. Zea AH, Rodriguez PC, Atkins MB et al. (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044-8